ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 134 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,616 | +65.6% | 173,813 | +76.5% | 0.00% | – |
| Q1 2024 | $976 | +178.1% | 98,505 | -9.3% | 0.00% | – |
| Q4 2023 | $351 | -68.1% | 108,660 | -47.5% | 0.00% | -100.0% |
| Q3 2023 | $1,099 | -50.6% | 207,077 | -11.3% | 0.00% | 0.0% |
| Q2 2023 | $2,224 | -84.8% | 233,418 | -82.5% | 0.00% | -85.7% |
| Q1 2023 | $14,631 | -16.3% | 1,330,065 | +12.7% | 0.01% | -12.5% |
| Q4 2022 | $17,470 | -99.4% | 1,180,384 | +738.1% | 0.01% | +166.7% |
| Q3 2022 | $2,691,000 | +262.7% | 140,837 | +304.3% | 0.00% | – |
| Q2 2022 | $742,000 | +1.6% | 34,836 | -8.2% | 0.00% | -100.0% |
| Q1 2022 | $730,000 | – | 37,938 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $305,003,000 | 24.46% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $115,121,000 | 6.52% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $16,462,000 | 5.28% |
| SECTORAL ASSET MANAGEMENT INC | 878,948 | $25,428,000 | 1.93% |
| Omega Fund Management, LLC | 623,836 | $18,048,000 | 1.71% |
| Orbimed Advisors | 6,073,850 | $175,716,000 | 1.64% |
| Altium Capital Management LP | 113,962 | $3,297,000 | 0.92% |
| Vivo Capital, LLC | 744,370 | $21,535,000 | 0.76% |
| Polar Capital Holdings Plc | 1,557,543 | $45,060,000 | 0.28% |
| Birchview Capital, LP | 9,000 | $260,000 | 0.15% |